Anti-fibrotic drugs dealing with pulmonary fibrosis after COVID-19-associated acute respiratory distress syndrome

作     者：Abhijit S.Nair Sai Kaushik Pulipaka Praveen Kumar Kodisharapu Asiel Christopher Abhijit S.Nair;Sai Kaushik Pulipaka;Praveen Kumar Kodisharapu;Asiel Christopher

作者机构：Department of AnaesthesiologyIbra HospitalNorth Sharqiya GovernorateIbra-414Sultanate of Oman Department of AnaesthesiologyBasavatarakam Indo-American Cancer Hospital and Research InstituteHyderabad-500034Telangana StateIndia 

出 版 物：《Journal of Acute Disease》 (急性病杂志（英文版）)

年 卷 期：2021年第10卷第4期

页      面：177-178页

学科分类：1002[医学-临床医学] 10[医学] 

主　　题：ACE2 drugs damage after 

摘      要：Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),the virus which is responsible for coronavirus disease(COVID-19),uses an angiotensin-2-converting enzyme(ACE2)as a cell receptor in humans.Initially,there is interstitial lung damage after infection,and then parenchymal lesions appear,which if not managed appropriately could worsen.Available data suggests that around 40%of patients with COVID-19 develop acute respiratory distress syndrome(ARDS),and 20%of these patients who develop ARDS require invasive and advanced modes of ventilation[1].